A device that is intended to cut the risk of embolism during transcatheter aortic valve replacement (TAVR) procedures – but showed uneven results in recent clinical trial data – will be up for discussion during the first US FDA device advisory panel meeting announced for 2017.
The Circulatory System Devices Panel plans to meet Feb. 23 in Gaithersburg, Md., to discuss the de novo application for Claret Medical Inc.’s Sentinel cerebral protection system, a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?